A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC

Inclusion Criteria: * 1\. Age 18 to 75 years. * 2.ECOG 0-1 points. * 3\. The expected survival time is more than 3 months. * 4\. Patients with advanced ccRCC confirmed by histology or cytology to be recurrent or metastatic after at least first-line treatment. * 5\. IHC: CD70 positive. * 6\. At least one measurable lesion at baseline per RECIST version 1.1. * 7\. The functions of important organs are basically normal: * 8\. Pregnancy tests for women of childbearing age shall be negative, both men and women agreed to use effective contraception. Exclusion Criteria: * 1\. Use of cell therapy within the previous one month. * 2\. Subjects with other malignant tumors within the past 2 years, except basal or squamous skin cancer, superficial bladder cancer, and breast cancer in situ, have been completely cured and do not need follow-up treatment. * 3\. Patients with leptomeningeal metastasis or central nervous system metastasis, and definite central nervous system underlying diseases with significant symptoms. * 4\. Immunotherapy, targeted drug therapy or chemotherapy within 5 drug half-lives within 2 weeks before cell infusion. * 5\. Active hepatitis B, HIV positive and HCV positive. * 6\. Active infection or uncontrollable infection. * 7\. Uncontrollable or significant heart disease. * 8\. Unstable respiratory diseases, including interstitial pneumonia. * 9\. Uncontrolled ascites and pleural effusion. * 10.Known to have active or uncontrolled autoimmune diseases, such as Crohns disease, rheumatoid arthritis, systemic lupus erythematosus, etc. * 11.Subjects who are using systemic steroids or steroid inhalers for treatment. * 12.Pregnant or lactating female subjects. * 13.Other investigators deem it unsuitable to participate in the study